Revisiting PhaseBio

Article feature image

Photo by santoelia/iStock via Getty Images
“Perseverance, secret of all triumphs.”― Victor Hugo
Today, we circle back on PhaseBio (NASDAQ:PHAS) for the first time since we penned an article on this ‘Tier 4’ developmental concern late in 2019. The company recently did a capital raise, and not surprisingly also has seen an uptick of positive analyst coverage over the past couple of months. It seems an appropriate time to revisit this small-cap concern. A full analysis follows below.
Company Overview:

Click here to view the original article.

S&P/ASX 200 
7,030.80  16.60  0.24%  
ALL ORDINARIES 
7,262.10  22.70  0.31%  
Dow Jones Industrial Average 
34,382.13  360.73  1.06%  
S&P 500 
4,173.85  61.35  1.49%  
NASDAQ Composite 
13,429.98  304.98  2.32%  
NYSE COMPOSITE (DJ) 
16,415.36  233.76  1.44%  
FTSE 100 
7,043.61  80.28  1.15%  
DAX PERFORMANCE-INDEX 
15,416.64  216.94  1.43%  
Nikkei 225 
27,963.81  120.66  0.43%  
HANG SENG INDEX 
28,027.57  308.87  1.11%